ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2900

Clinically Inactive Disease in Juvenile Dermatomyositis – a Proposed Revision to the Pediatric Rheumatology International Trials Organisation Criteria

Beverley Almeida1, Raquel Campanilho-Marques2, Katie Arnold2, Lucy R. Wedderburn3,4, Clarissa A Pilkington5 and Kiran Nistala6, 1Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 2Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, 3Institute of Child Health, University College London, London, United Kingdom, 4Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, 5Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 6Centre for Rheumatology, University College London, London, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Disease Activity, juvenile dermatomyositis, remission and skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Miscellaneous Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Juvenile dermatomyositis (JDM) affects 3 children/million/year with myositis and skin disease being the typical features. The Pediatric Rheumatology International Trials Organisation (PRINTO) have recently established criteria to classify JDM patients who are clinically inactive by meeting at least 3 out of the following 4 conditions – Creatine Kinase (CK) ≤150 U/L, Childhood Myositis Assessment Score (CMAS) ≥48, Manual Muscle Testing of 8 groups (MMT8) ≥78 and physician global Visual Analogue Scale (PGA) ≤0.2. CK, CMAS and MMT8 all measure muscle involvement, only PGA includes skin or other organ involvement. The hypothesis that these criteria may fail to detect patients who have active skin disease but normal muscle parameters was tested.  The aim was to demonstrate the prevalence of clinically inactive disease in the UK JDM Cohort and Biomarker Study and to identify whether skin disease is still present in these patients on the basis of the PRINTO criteria.

Methods: Data were analysed from children who were recruited and met Bohan-Peter criteria. Data from patient episodes (either a clinic visit or hospital admission) were assessed using the PRINTO criteria. Using the PRINTO rules stipulating 3 of 4 criteria are required, all data entries were divided into 2 groups based on the criterion that was omitted. Each case was analysed to determine whether skin disease was present or absent.

Results: 682 data entries (DE) from 321 patients were identified as clinically inactive. 255 (37.4%) of these DE (119 patients) met all 4 criteria. 21.2% of DE had skin rash and 10.5% had nailfold changes (Table 1) at the time of assessment. 427 of the total DE (202 patients) met 3 of the 4 criteria. Of these, 320 (74.9%) had clinically inactive based on the 3 muscle criteria (PGA was not met). 61.6% of this group had ongoing skin rash present. Among the 107 remaining DE, which were clinically inactive by 3 criteria of which one was PGA, the frequency of skin changes was lower. The differences between the 3 groups were statistically significant in terms of rash (χ2 111.5, p<0.0001), nailfold changes (χ2 65.5, p<0.0001) and calcinosis (χ2 22.07, p<0.0001).

Table 1: Frequency of skin changes in JDM patients meeting PRINTO criteria (number of episodes, % in brackets)

No. of criteria met (DE=data entries, n=number of patients)

Rash

Nailfold changes

Calcinosis

All 4 criteria met (255 DE, n 119)

54 (21.2)

27 (10.5)

19 (7.5)

3 criteria met, but PGA not met (320 DE, n 131)

197  (61.6)

114 (35.6)

60 (18.8)

3 criteria met of which one was PGA (107 DE, n 71)

25 (23.3)

9 (8.4)

6 (5.6)

Conclusion: This study is one of the first to test the PRINTO criteria in a large independent cohort of JDM patients. When clinically inactive disease is defined by “muscle-based” criteria, without PGA, there is a greater frequency of skin disease. As a revision, we propose that PGA should be included as an essential criterion together with 2 of the 3 muscle criteria. This would prevent skin disease being overlooked in the clinical assessment which is important since it is often recalcitrant to treatment and may be associated with poor long-term disease outcomes. A revision of the criteria would need testing in independent cohorts.


Disclosure:

B. Almeida,
None;

R. Campanilho-Marques,
None;

K. Arnold,
None;

L. R. Wedderburn,
None;

C. A Pilkington,
None;

K. Nistala,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinically-inactive-disease-in-juvenile-dermatomyositis-a-proposed-revision-to-the-pediatric-rheumatology-international-trials-organisation-criteria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology